Navigation Links
Growing Awareness & Increasing Number of Indications Drive the Global Intravenous Immunoglobulin Market, According to a New Report by Global Industry Analysts, Inc.

San Jose, California (PRWEB) July 09, 2013

Follow us on LinkedIn – Immunoglobulins administered through the intravenous route (IVIg) are the most important blood plasma proteins used in the treatment of a variety of labeled and unlabeled indications. The global Intravenous Immunoglobulin (IVIg) market is forecast to witness strong growth supported by increasing acceptance among patients as awareness about the indications for which the protein can be prescribed rises. Increasing population and life expectancy is one of the key factors driving growth of IVIg consumption at the global level and the trend will continue to influence the market positively in the coming years. Approval of new indications and improved diagnosis of conditions are expected to wield a positive effect on the market in the near future. One of the key growth drivers for IVIg is be the protein’s increasing use in immune-mediated neurological disorders and primary immunodeficiencies.

IVIg is also finding increased usage in emerging countries on account of rapid medical technology development, favorable demographics and increasing awareness about treatment with plasma proteins. Expansion of healthcare in developing markets will also be a key growth driving factor for the protein. China, with vast unmet medical needs and a very low per capita consumption, offers robust opportunities for growth. The nation is touted to emerge as one of the leading IVIg consuming markets. Other factors to drive growth in developing countries include improvement in health service provision, increasing funding and expanding range of therapeutic indications for IVIg. On the other hand, key factors with the potential to challenge growth in the medium-to-long term period include healthcare cost containment efforts in industrialized countries; while in emerging countries, the high cost of the therapy has the potential to stifle market expansion.

The potential approval of IVIg products for Alzheimer’s disease in the next few years, and off-label usage of the same over the intervening period is forecast to positively benefit the market. Advances in research have revealed that Intravenous Immunoglobulin (IVIg) fraction from normal human donor blood demonstrates potential to provide passive immunotherapy for Alzheimer’s disease. IVIg could help treat the underlying cause of Alzheimer’s, while also slowing down symptoms of the disease. On the other hand, the positive results of ongoing studies also bring to fore certain issues the industry might possibly face in the event of IVIg showing success in slowing down progress of the Alzheimer’s disease. The question of whether or not the existing plasma manufacturers are capable of adequately meeting the anticipated significant rise in demand will be the most important among such issues.

The market continues to witness structural reformations such as mergers, vertical integrations, and increased manufacturing competencies in a bid for stable growth and market proliferation. The global market for IVIg is currently led by CSL Limited. Other key market participants include Grifols, Baxter and Octapharma. A notable event in the industry during 2010-2011 was the suspension of the marketing activity of Octapharma’s Octagam, one of the leading IVIg products in the industry. The suspension benefited other leading players including Grifols and Baxter, in the form of increase in volume sales of their IVIg products.

As stated by the new market research report on
Intravenous Immunoglobulin (IVIg), the United States represents the largest market, followed by Europe. Asia-Pacific led by China is projected to offer the highest growth opportunity.

Major players in the market include Baxter International Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Limited, Biotest AG, China Biologic Products Inc., CSL Limited, CSL Behring LLC., Grifols, S.A, Hualan Biological Engineering Inc., Kedrion S.p.A, LFB Group, Octapharma AG, OMRIX Biopharmaceuticals Ltd., Shanghai RAAS Blood Products Co. Ltd., and Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.

The research report titled "Intravenous Immunoglobulin (IVIg): A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the intravenous immunoglobulin market as well as the plasma products and immunoglobulins markets, current trends, growth drivers, product approvals, product launches, and recent industry activity. The report provides annual revenue estimates and projections in terms of value (US$) by the following geographic markets – The US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (Australia, China and Rest of Asia-Pacific) and Rest of World.

For more details about this comprehensive market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Newborn Calf Serum Added to Growing Product Suite of Rocky Mountain Biologicals
2. Probiotic Action Comments on the New Use of Probiotics for Oral Health and Shares New Insight What It Means for the Growing US Probiotic Market
3. Apache Atmospheric Tanks Support Growing Biofuel Industry for Sanimax
4. NanoSight, One of the UKs Fastest Growing Biotechnology Companies, Wins a 2013 Queens Award for Enterprise - Innovation
5. Professional Pricing Society Survey Reveals 12 Percent Gain in Manufacturing and Distribution Salaries, Indicating Growing Value of Pricing Expertise
6. Growing Uptake of Genzymes Aubagio at Three Months Post-Launch Is Likely Driven by Perceived Product Convenience Even As Neurologists Search to Identify Appropriate Candidates, According to a Recent BioTrends Report
7. Rapidly Growing Company Extends Global Reach
8. BioInformatics LLC New Market Report – Opportunities for New Players in the Growing Stem Cell Market
9. The 2013 CES: Patents, Legislation Reform, and the Growing Market for Patent Attorneys and Agents Reviewed by Wysebridge
10. Growing Job-Market Niche Inside The Economic Decline: A Wysebridge Review
11. Ramey & Browning Announces New Location and New Hire Firm Is Well Positioned to Address Growing Client Needs In 2013
Post Your Comments:
(Date:3/29/2017)... ... March 29, 2017 , ... On the heels of the globally ... Clinical Trial Travel has announced that it will manage travel services for its 500th ... first in the United States and Europe to offer travel management services specifically for ...
(Date:3/29/2017)... and NEWARK, Del. , March ... privately-held regenerative medicine company, and W. L. Gore ... company, today announced a collaborative research agreement whereby the ... cell therapy delivery device technologies that provide protection from ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... with the American Association for the Advancement of Science (AAAS), the world's ... partnership, ReadCube will enhance its high-impact scholarly collection across its cross-platform reference ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation ... over two years to develop a suite of BioGel™ biopolymer materials for hygiene ...
Breaking Biology Technology:
(Date:3/7/2017)... BRIGHTON, England , March 7, 2017 Brandwatch ... been chosen by The Prince,s Trust to uncover insights ... insights across The Trust. The UK,s leading youth charity ... track social campaign results and get a better understanding of the ... ...
(Date:3/2/2017)... , March 2, 2017 Summary ... understand Perrigo and its partnering interests and activities since 2010. ... Read ... Deals and Alliance since 2010 report provides an in-depth insight ... life sciences companies. On demand company reports are ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):